Question special
Moderator

Considering that Idarucizumab is a mouse monoclonal antibody that directly targets Dabigatran, are there concerns for immunogenecity (with regards to long term safety and subsequent treatments with the anticoagulant Dabigatran and its reversal agent Idarucizumab) ?